News for NARI Stock

Masimo Announces Leadership Transition Inari Medical to Present at the J.P. Morgan Healthcare Conference Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd. Inari Medical Announces Joint Venture in Greater China Inari Medical to Participate in the Jefferies London Healthcare Conference PEERLESS Results Show Superiority of FlowTriever® Compared to Catheter-Directed Thrombolytics for Intermediate-Risk Pulmonary Embolism Inari Medical Reports Third Quarter 2024 Financial Results Okami Medical Announces Closing Of $32.5M Financing Inari Medical to Host Analyst and Investor Meeting Following PEERLESS RCT Presentation Inari Medical to Announce Third Quarter 2024 Financial Results Inari Medical Announces PEERLESS Data to be Presented During the Late-Breaking Clinical Trial Sessions at TCT 2024 Inari Medical to Present at Upcoming Investor Conferences Inari Medical Announces Chief Financial Officer Retirement and Succession Plan Inari Medical Reports Second Quarter 2024 Financial Results Inari Medical to Announce Second Quarter 2024 Financial Results Inari Medical Files Patent Infringement Lawsuit Against Imperative Care and Truvic Medical Inari Medical to Participate in the 2024 Bank of America Securities Healthcare Conference Inari Medical Reports First Quarter 2024 Financial Results Inari Medical to Announce First Quarter 2024 Financial Results Inari Medical Announces the Release of 2023 Ethos and Sustainability Report Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives Inari Medical Announces Interim Two-Year Results from the ClotTriever CLOUT Registry Inari Medical Reports Fourth Quarter 2023 Financial Results Inari Medical to Announce Fourth Quarter and Full Year 2023 Financial Results Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance OKAMI MEDICAL APPOINTS RHONDA ROBB AS PRESIDENT AND CHIEF EXECUTIVE OFFICER Inari Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference Inari Medical Announces First Patient Enrollment in PEERLESS II Randomized Controlled Trial (RCT) Inari Medical Closes Acquisition of LimFlow Inari Medical to Present at Upcoming Investor Conferences LimFlow Announces Agreement to Be Acquired by Inari Medical Inari Medical Reports Third Quarter 2023 Financial Results Inari Medical Expands Its Patient-Focused Mission with Agreement to Acquire LimFlow Inari Medical to Announce Third Quarter 2023 Financial Results Inari Medical to Present at Upcoming Investor Conferences Inari Medical Reports Second Quarter 2023 Financial Results Inari Medical to Present at the 43rd Annual Canaccord Growth Conference Inari Medical to Announce Second Quarter 2023 Financial Results Inari Medical Announces Commercial Launch of RevCore™ and Triever16 Curve™, Two New Purpose-Built Products for Addressing Venous Stent Thrombosis and Venous Thromboembolism Inari Medical Announces the Release of 2022 Ethos and Sustainability Report Inari Medical Announces PEERLESS II, a Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System vs. Anticoagulation in Pulmonary Embolism Patients Inari Medical Reports First Quarter 2023 Financial Results Inari Medical to Present at the Bank of America 2023 Healthcare Conference Inari Medical to Announce First Quarter 2023 Financial Results FLAME Study Demonstrates 90% Survival Improvement in High-Risk Pulmonary Embolism with Inari Medical FlowTriever System Inari Medical Reports Fourth Quarter and Full Year 2022 Financial Results Inari Medical to Announce Fourth Quarter and Full Year 2022 Financial Results Inari Medical to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference Inari Medical Announces First Patient Enrolled in the DEFIANCE Trial, Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis Inari Medical Announces Preliminary 2022 Revenue and 2023 Guidance Inari Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference Inari Medical to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Inari Medical Reports Third Quarter 2022 Financial Results Inari Medical Announces In-hospital and 30-day Outcomes from the Fully Enrolled CLOUT Registry and Results from Propensity-Score Matched Comparison of CLOUT vs. ATTRACT Inari Medical to Announce Third Quarter 2022 Financial Results Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry Inari Medical to Host First Analyst & Investor Day Inari Medical Announces Three New Data Sets to be Presented During Late-Breaking Clinical Trial Sessions at the 2022 TCT and VEINS Conferences Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the ClotTriever® System in Deep Vein Thrombosis Inari Medical to Present at Upcoming Investor Conferences Inari Medical Announces Leadership Succession Plan Inari Medical Reports Second Quarter 2022 Financial Results Inari Medical to Announce Second Quarter 2022 Financial Results OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDERS TO ADDRESS A WIDE RANGE OF PERIPHERAL EMBOLIZATION CASES Inari Medical Announces Launch of 2021 Ethos and Sustainability Report Inari Medical Reports First Quarter 2022 Financial Results Inari Medical to Present at the Bank of America 2022 Healthcare Conference Inari Medical to Announce First Quarter 2022 Financial Results Inari Medical Announces Closing of Underwriters’ Over-Allotment Option in Connection with Offering of Common Stock Inari Medical Announces Pricing of Offering of Common Stock Inari Medical Announces Proposed Offering of Common Stock Inari Medical Appoints Robert Warner to Board of Directors Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results Inari Medical Announces First Patient Enrolled in the PEERLESS Trial, a Randomized Controlled Trial Evaluating Outcomes of the FlowTriever® System in Pulmonary Embolism Patients Inari Medical to Announce Fourth Quarter and Full-Year 2021 Financial Results Inari Medical to Present at Upcoming Investor Conferences Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue Inari Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference Inari Medical Reports Third Quarter 2021 Financial Results Inari Medical Announces 6-month FLASH Registry Interim Data Demonstrating Benefits of Lytic-Free Mechanical Thrombectomy in 500 Real-World PE Patients Inari Medical to Announce Third Quarter 2021 Financial Results Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System in Pulmonary Embolism Patients Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors Inari Medical Appoints Pulmonologist Dr. Victor F. Tapson as VP of Medical Affairs Inari Medical to Present at Upcoming Investor Conferences Inari Medical Reports Second Quarter 2021 Financial Results  Inari Medical to Present at the Canaccord Genuity 41st Annual Growth Conference Inari Medical to Announce Second Quarter 2021 Financial Results Inari Medical Appoints Outset Medical Executive Rebecca Chambers to Board of Directors Inari Medical Announces Late-Breaking CLOUT Registry Data Demonstrating Long-Term Benefits of Lytic-Free Single-Session Near Bloodless Thrombectomy in First 250 Real-World DVT Patients Inari Medical Reports First Quarter 2021 Financial Results Inari Medical to Present at the 2021 Bank of America Healthcare Conference Inari Medical to Announce First Quarter 2021 Financial Results Inari Medical Announces Global Partnership with Aidoc to Advance the Timely Detection and Treatment of Pulmonary Embolism Inari Medical Announces First Patient Enrolled in FLAME Study Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results Inari Medical to Announce Fourth Quarter and Full Year 2020 Financial Results Inari Medical to Present in Upcoming Investor Conferences Inari Medical Announces Presentation of Positive Chronic Clot Subanalysis Results from Real World CLOUT Registry at LINC 2021 Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue Inari Medical’s FlowTriever System Receives FDA 510(k) Clearance for Treatment of Right Atrial Clot in Transit Inari Medical Appoints Venkat Tummala as VP of Medical Affairs and Justin Crockett as VP of Inari Solutions Group Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry Inari Medical Reports Third Quarter 2020 Financial Results Inari Medical Appoints Kevin Strange as VP of Strategy and Business Development and Angela Ahmad as General Counsel Inari Medical to Participate at the Canaccord Genuity Virtual MedTech & Diagnostics Forum Inari Medical to Announce Third Quarter 2020 Financial Results Inari Medical Announces Presentation of Positive Results from First Patients in Real World FLASH Registry Inari Medical Prospective Clinical Data on the FlowTriever System to be Presented in Late-Breaking Session at TCT Connect Inari Medical Announces Promotion of Drew Hykes to Chief Operating Officer Inari Medical to Participate in Upcoming Investor Conferences Inari Medical Announces Pricing of Its Upsized Initial Public Offering Inari Medical to Present at the Canaccord Genuity 40th Annual Growth Conference Inari Medical Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares Inari Medical to Announce Second Quarter 2020 Financial Results